Project coordinator and leader of WP2 on advanced characterisation.
Specialised in synchrotron based characterisation techniques.
Expertise in dimensional analysis and number concentration measurement of NPs by X-ray scattering.
WP1 Leader.
Contributes to WP2, WP3, and WP4 with optical characterization and analytical methods.
Producer of reference materials and involved in standardisation activities.
WP4 Leader.
Offers expertise in advanced microscopy technologies, biochemical analysis, and micro/nanomaterial characterization.
WP3 leader, leading the development of sample preparation and particle fractionaction approaches (e.g. FFF)
Expert in electron microscopy, AFM and artificial intelligence tools for nanoparticle image analysis
Contributing to develop inductively coupled plasma mass spectrometry approaches for particle detection (scICP-MS)
WP5 Leader.
Facilitates strategic thinking and clinical translation of innovative nanomedicine projects in Europe.
In charge of Creating Impact for METRINO (Communication, Dissemination, Exploitation).
Involvement in WP3 for dimensional characterization.
Contributes to WP1 with nanoparticle design and synthesis.
Offers nanomaterial expertise, especially in X-ray scattering.
Provides lipid-based nanomaterials and supports preclinical evaluation activities.
Supplies HfO2 nanoparticles and investigates their storage and stability.
Contributes iron oxide nanoparticles for standard reference material development.
Provides clinical insights and supports innovative microscopy techniques.
Offers expertise in biomedicine and medical imaging.
Specialises in analytical methods for nanoparticle characterization.
Brings expertise in ICP-MS for nanoparticle detection.
Provides characterization methods for lipid-based nanoparticles.
Contributes particle-biology interaction expertise.
Contributes to nanoparticle measurement and chemical analysis.
Together, we form a mosaic of scientific inquiry and innovation. The METRINO consortium is dedicated to harmonising the way we measure nanomedicine's smallest constituents. Our collective pursuit is to ensure these groundbreaking therapies are as precise as they are promising.
Get involved!
The METRINO project has received funding from the European Partnership on Metrology (Grant #22HLT04), co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.